Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

15:34
10/09/16
10/09
15:34
10/09/16
15:34

Merck reports long-term data from final KEYNOTE-002 analysis

Merck announced findings from the final overall survival analysis from the KEYNOTE-002 study investigating the use of Keytruda compared to investigator-choice chemotherapy with a crossover to Keytruda design, in patients with ipilimumab-refractory advanced melanoma. The results presented at the ESMO 2016 Congress include follow-up of up to 35 months for the study's co-primary endpoints of OS and progression-free survival. Data showed prolonged OS with Keytruda 2 mg/kg and 10 mg/kg, with a median OS of 13.4 months and 14.7 months and a two-year OS rate of 35.9 percent and 38.2 percent, respectively, compared to a median OS of 11.0 months and a two-year OS rate of 29.7 percent with chemotherapy. While improvements in OS between Keytruda 2 mg/kg or 10 mg/kg and chemotherapy did not meet the protocol-specified significance threshold, longer follow-up continued to show a clinically meaningful improvement in PFS, the study's co-primary endpoint, with PFS of up to 31 months in patients treated with Keytruda. Median PFS was approximately three months for each of the patient groups -- 2.8-3.8 months with Keytruda 2 mg/kg; 2.8-5.2 months with Keytruda 10 mg/kg; and 2.6-2.8 months with chemotherapy. The two-year PFS rate was 16.0 percent and 21.9 percent with Keytruda compared to 0.6 percent of patients treated with chemotherapy. ORR was 22.2 percent and 27.6 percent with Keytruda compared to 4.5 percent with chemotherapy. At the time of analysis, 50 percent and 58 percent of patients who responded to Keytruda were alive with no subsequent progression or anti-tumor therapy, compared to 12 percent of patients who responded to chemotherapy. With longer follow-up, adverse events have remained consistent with previously reported safety data.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

RDUS

Radius Health

$38.72

-0.5 (-1.27%)

10:12
04/28/17
04/28
10:12
04/28/17
10:12
Hot Stocks
FDA website shows approval of Radius Health's Tymlos »

Shares of Radius Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 02

    Jun

  • 30

    Jun

WDC

Western Digital

$85.71

1.1 (1.30%)

10:11
04/28/17
04/28
10:11
04/28/17
10:11
Recommendations
Western Digital analyst commentary  »

Western Digital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$10.50

0.14 (1.35%)

10:11
04/28/17
04/28
10:11
04/28/17
10:11
Options
Opening action in VIX August calls »

Opening action in VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLDR

Cloudera

10:10
04/28/17
04/28
10:10
04/28/17
10:10
Syndicate
Breaking Syndicate news story on Cloudera »

Cloudera IPO indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

NVS

Novartis

$76.70

-0.36 (-0.47%)

10:10
04/28/17
04/28
10:10
04/28/17
10:10
Hot Stocks
FDA approves Novartis' combination treatment for AML »

The U.S. Food and Drug…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 05

    May

  • 07

    May

  • 06

    Jun

  • 26

    Jun

SWKS

Skyworks

$104.20

1.23 (1.19%)

, SSNLF

Samsung

10:09
04/28/17
04/28
10:09
04/28/17
10:09
Recommendations
Skyworks, Samsung analyst commentary  »

Skyworks price target…

SWKS

Skyworks

$104.20

1.23 (1.19%)

SSNLF

Samsung

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 30

    May

RDUS

Radius Health

$38.72

-0.5 (-1.27%)

10:07
04/28/17
04/28
10:07
04/28/17
10:07
Hot Stocks
Radius Health jumps after FDA posts approval of Tymlos 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 03

    May

  • 02

    Jun

  • 30

    Jun

ORLY

O'Reilly Automotive

$257.19

-7.88 (-2.97%)

10:02
04/28/17
04/28
10:02
04/28/17
10:02
Recommendations
O'Reilly Automotive analyst commentary  »

O'Reilly Automotive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

MHK

Mohawk

$229.91

-8.97 (-3.76%)

10:01
04/28/17
04/28
10:01
04/28/17
10:01
Technical Analysis
Mohawk testing uptrend support line following earnings »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

10:01
04/28/17
04/28
10:01
04/28/17
10:01
General news
Consumer Sentiment Index data reported »

April Consumer Sentiment…

CL

Colgate-Palmolive

$72.10

-1.2 (-1.64%)

10:01
04/28/17
04/28
10:01
04/28/17
10:01
Options
Call buyer in Colgate as shares fall on earnings »

Call buyer in Colgate as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 31

    May

EEX

Emerald Expositions Events

10:00
04/28/17
04/28
10:00
04/28/17
10:00
Syndicate
Breaking Syndicate news story on Emerald Expositions Events »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

IVC

Invacare

$14.85

1.6 (12.08%)

09:59
04/28/17
04/28
09:59
04/28/17
09:59
Upgrade
Invacare rating change  »

Invacare upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 18

    May

CVNA

Carvana

09:58
04/28/17
04/28
09:58
04/28/17
09:58
Syndicate
Breaking Syndicate news story on Carvana »

Carvana opens at $13.50,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

EFX

Equifax

$134.84

-1.35 (-0.99%)

09:56
04/28/17
04/28
09:56
04/28/17
09:56
Downgrade
Equifax rating change  »

Equifax downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 04

    May

EEX

Emerald Expositions Events

09:55
04/28/17
04/28
09:55
04/28/17
09:55
Syndicate
Breaking Syndicate news story on Emerald Expositions Events »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

09:55
04/28/17
04/28
09:55
04/28/17
09:55
General news
U.S. Chicago PMI increased 0.6 points to 58.3 in April »

U.S. Chicago PMI…

CSGP

CoStar Group

$236.71

17.35 (7.91%)

09:53
04/28/17
04/28
09:53
04/28/17
09:53
Recommendations
CoStar Group analyst commentary  »

CoStar Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

BOKF

BOK Financial

$85.04

-0.42 (-0.49%)

09:51
04/28/17
04/28
09:51
04/28/17
09:51
Upgrade
BOK Financial rating change  »

BOK Financial upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

OCLR

Oclaro

$7.93

0.01 (0.13%)

09:51
04/28/17
04/28
09:51
04/28/17
09:51
Recommendations
Oclaro analyst commentary  »

Oclaro estimates lowered …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 30

    May

BSX

Boston Scientific

$26.16

-0.02 (-0.08%)

09:51
04/28/17
04/28
09:51
04/28/17
09:51
Options
Active trading in Boston Scientific short-term calls »

Active trading in Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 07

    Jun

  • 27

    Jun

EEX

Emerald Expositions Events

09:50
04/28/17
04/28
09:50
04/28/17
09:50
Syndicate
Breaking Syndicate news story on Emerald Expositions Events »

Emerald Expositions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

09:50
04/28/17
04/28
09:50
04/28/17
09:50
General news
The hefty 0.8% U.S. Q1 ECI gain »

The hefty 0.8% U.S. Q1…

ZYME

Zymeworks

09:49
04/28/17
04/28
09:49
04/28/17
09:49
Syndicate
Breaking Syndicate news story on Zymeworks »

Zymeworks opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

XRF

China Rapid Finance

09:48
04/28/17
04/28
09:48
04/28/17
09:48
Syndicate
Breaking Syndicate news story on China Rapid Finance »

China Rapid Finance opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.